Benjamin Kasenda

Prevalence, Characteristics, and Publication of Discontinued Randomized Trials

Benjamin Kasenda, Erik von Elm, John J. You et al. · JAMA · 2014 · 430 citations · Full text

Public Health, Public Health Ethics, Clinical Epidemiology +16

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Stefan Diem, Benjamin Kasenda, Lavinia Spain et al. · British Journal of Cancer · 2016 · 308 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

Michal A. Stanczak, Natália Rodrigues Mantuano, Nicole Kirchhammer et al. · Science Translational Medicine · 2022 · 231 citations · Full text

Life Sciences, Immunology, Oncology +17

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

Kristina Fritsch, Benjamin Kasenda, Elisabeth Schorb et al. · Leukemia · 2016 · 183 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial

Gerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst et al. · The Lancet Haematology · 2016 · 169 citations

Medicine, Hematology, Oncology +15